ARNI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 bal. 2024 @ 17:25):

Stats
Šios dienos apimtis	3 500.00
Vidutinė apimtis	61.00
Rinkos kapitalizacija	177 659
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2016-08-15	Belldegrun Arie	Buy	714 285	Common Stock
2016-08-15	Belldegrun Arie	Buy	357 142	2016 Series F Warrants (right to buy)

INSIDER POWER
0.00
Last 89 transactions
Buy: 17 291 951 \| Sell: 681 614

Tūris Koreliacija

Ilgas: -0.51 (weak negative)

Trumpas: -0.35 (neutral)

Signal:(10.878) Neutral

Arno Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Arno Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

Arno Therapeutics, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2015
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.560

FY	2014
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0.380

Financial Reports:

No articles found.

Arno Therapeutics, Inc.

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.